Esperion Therapeutics Dividends
| ESPR Stock | USD 3.44 0.01 0.29% |
As of 02/16/2026, Dividend Paid And Capex Coverage Ratio is likely to drop to -90.1. Esperion Therapeutics' past performance could be the main factor of why investors trade Esperion Therapeutics stock today. Investors should clearly understand every aspect of the Esperion Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Esperion Therapeutics' dividend schedule and payout information. Esperion Therapeutics dividends can also provide a clue to the current valuation of Esperion Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (85.81) | (90.10) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Esperion Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Esperion Therapeutics Dividends Paid Over Time
Today, most investors in Esperion Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Esperion Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Esperion Therapeutics dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Can Biotechnology industry sustain growth momentum? Does Esperion have expansion opportunities? Factors like these will boost the valuation of Esperion Therapeutics. Projected growth potential of Esperion fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Esperion Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.54) | Revenue Per Share | Quarterly Revenue Growth 0.691 | Return On Assets | Return On Equity |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Esperion Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Esperion Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Esperion Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.